1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES

related topics

{product, candidate, development}

{stock, price, share}

{regulation, government, change}

{competitive, industry, competition}

{product, liability, claim}

{provision, law, control}

{product, market, service}

{interest, director, officer}

{personnel, key, retain}

{customer, product, revenue}

Our new drug product requires FDA approval and expensive clinical trials before it can be marketed. Even if our new drug product is approved by the FDA it may not be successfully marketed. We may not be successful in improving our gross profit margins and our business may remain unprofitable. We depend on government funding of healthcare. We may not have sufficient cash to fund future growth or SFP development. Orders from our international distributors may not result in recurring revenue. We depend on key personnel. Our business is highly regulated. We depend on contract research organizations and consultants to manage and conduct our clinical trials and if they fail to follow our protocol or meet FDA regulatory requirements our clinical trial data and results could be compromised causing us to delay our development plans or have to do more testing than planned. Foreign approvals to market our new drug products may be difficult to obtain. Health care reform could adversely affect our business. We may not have sufficient products liability insurance. Our Board of Directors is subject to potential deadlock. RISKS RELATED TO OUR COMMON STOCK Shares eligible for future sale may affect the market price of our common shares. The market price of our securities may be volatile. Voting control and anti-takeover provisions reduce the likelihood that you will receive a takeover premium.

Full 10-K form ▸

1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES_INC